Products & Services · Total revenues
Aranesp — Total revenues
Amgen Aranesp — Total revenues decreased by 96.4% to $311M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 96.2%, from $8.15B to $311M. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ1 2019
Last reportedQ1 2026Apr 30, 2026
Rolls up toTotal Revenue
How to read this metric
An increase suggests strong market demand or effective pricing strategies, while a decrease may indicate market share erosion due to competition or a decline in clinical usage.
Detailed definition
This metric represents the total gross sales generated from the Aranesp product line, a therapeutic agent used to treat...
Peer comparison
Comparable to product-specific revenue reporting for mature biologic or specialty pharmaceutical assets at peer biotechnology companies.
Metric ID:
amgn_segment_aranesp_total_revenuesHistorical Data
40 periods
| Q2 '21 | Q2 '21 | Q3 '21 | Q3 '21 | Q4 '21 | Q4 '21 | Q1 '22 | Q1 '22 | Q2 '22 | Q2 '22 | Q3 '22 | Q3 '22 | Q4 '22 | Q4 '22 | Q1 '23 | Q1 '23 | Q2 '23 | Q2 '23 | Q3 '23 | Q3 '23 | Q4 '23 | Q4 '23 | Q1 '24 | Q1 '24 | Q2 '24 | Q2 '24 | Q3 '24 | Q3 '24 | Q4 '24 | Q4 '24 | Q1 '25 | Q1 '25 | Q2 '25 | Q2 '25 | Q3 '25 | Q3 '25 | Q4 '25 | Q4 '25 | Q1 '26 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $6.53B | $367M | $6.71B | $396M | $6.85B | $362M | $6.24B | $358M | $6.59B | $357M | $6.65B | $358M | $6.84B | $348M | $6.11B | $355M | $6.99B | $365M | $6.9B | $323M | $8.2B | $319M | $7.45B | $349M | $8.39B | $348M | $8.5B | $337M | $9.09B | $308M | $8.15B | $340M | $9.18B | $359M | $9.56B | $357M | $9.87B | $333M | $8.62B | $311M |
| QoQ Change | — | -94.4% | >999% | -94.1% | >999% | -94.7% | >999% | -94.3% | >999% | -94.6% | >999% | -94.6% | >999% | -94.9% | >999% | -94.2% | >999% | -94.8% | >999% | -95.3% | >999% | -96.1% | >999% | -95.3% | >999% | -95.9% | >999% | -96.0% | >999% | -96.6% | >999% | -95.8% | >999% | -96.1% | >999% | -96.3% | >999% | -96.6% | >999% | -96.4% |
| YoY Change | — | — | — | — | — | — | — | — | +1.0% | -94.5% | -0.8% | -94.7% | -0.1% | -94.9% | -2.1% | -94.3% | +5.9% | -94.5% | +3.8% | -95.1% | +19.8% | -95.3% | +22.0% | -94.3% | +20.1% | -95.0% | +23.2% | -95.1% | +10.9% | -96.2% | +9.4% | -95.4% | +9.4% | -95.7% | +12.4% | -95.8% | +8.6% | -96.3% | +5.8% | -96.2% |
Range$308M – $9.87B
CAGR-26.8%
Avg YoY Growth-42.9%
Median YoY Growth-48.2%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Amgen's aranesp — total revenues?
- Amgen (AMGN) reported aranesp — total revenues of $311M in Q1 2026.
- How has Amgen's aranesp — total revenues changed year-over-year?
- Amgen's aranesp — total revenues decreased by 96.2% year-over-year, from $8.15B to $311M.
- What does aranesp — total revenues mean?
- The total revenue generated from sales of the Aranesp therapeutic product.